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OBJECTIVE — The purpose of this study was to assess the efﬁcacy of the postload plasma
glucose concentration in predicting future risk of type 2 diabetes, compared with prediction
models based on measurement of the fasting plasma glucose (FPG) concentration.
RESEARCH DESIGN AND METHODS — A total of 2,442 subjects from the Botnia
Study, who were free of type 2 diabetes at baseline, received an oral glucose tolerance test
(OGTT)atbaselineandafter7–8yearsoffollow-up.Futureriskfortype2diabeteswasassessed
with area under the receiver-operating characteristic curve for prediction models based up
measurement of the FPG concentration 1) with or without a 1-h plasma glucose concentration
during the OGTT and 2) with or without the metabolic syndrome.
RESULTS — Prediction models based on measurement of the FPG concentration were weak
predictors for the risk of future type 2 diabetes. Addition of a 1-h plasma glucose concentration
markedly enhanced prediction of the risk of future type 2 diabetes. A cut point of 155 mg/dl for
the1-hplasmaglucoseconcentrationduringtheOGTTandpresenceofthemetabolicsyndrome
were used to stratify subjects in each glucose tolerance group into low, intermediate, and high
risk for future type 2 diabetes.
CONCLUSIONS — The plasma glucose concentration at 1 h during the OGTT is a strong
predictor of future risk for type 2 diabetes and adds to the prediction power of models based on
measurements made during the fasting state. A plasma glucose cut point of 155 mg/dl plus the
AdultTreatmentPanelIIIcriteriaforthemetabolicsyndromecanbeusedtostratifynondiabetic
subjects into low-, intermediate-, and high-risk groups.
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eliable models for identiﬁcation of
individuals at high risk for future
type 2 diabetes are essential and
have important clinical implications for
intervention programs. Because subjects
with impaired glucose tolerance (IGT)
have an increased risk for future type 2
diabetes (1), the oral glucose tolerance
test (OGTT) has become the standard
method for identifying individuals at risk
fordevelopingtype2diabetes.Indeed,all
clinical trials that have assessed strategies
for type 2 diabetes prevention have re-
cruited subjects with IGT (2). However,
performance of an OGTT is time consum-
ing, and models based on measurement of
thefastingplasmaglucose(FPG)concentra-
tion and plasma lipid proﬁle, in addition to
medical history and anthropometric mea-
surements, have been developed to predict
the future risk of type 2 diabetes (3–8). Of
note,IGTconvertstotype2diabetesinonly
50% of subjects within 10 years of fol-
low-up (1). Moreover, in longitudinal epi-
demiologicalstudies40%ofsubjectswho
develop type 2 diabetes have normal glu-
cosetolerance(NGT)atbaseline,indicating
that there is a population of subjects with
NGT who are at risk for future type 2 dia-
betes (1).
Wehavedemonstratedthat,although
subjects with NGT have a relatively low
risk for the future development of type 2
diabetes, a group of subjects with NGT
with an increased risk for diabetes can be
identiﬁed on the basis of the relationship
between their postload and FPG concen-
trations (9) or on the 1-h plasma glucose
concentration and presence of the meta-
bolic syndrome (10).
Insulin resistance and impaired insu-
lin secretion represent the characteristic
pathophysiologic disturbances responsi-
ble for development of type 2 diabetes
(11,12). Although both insulin resistance
and -cell dysfunction are present long
before the onset of diabetes, progressive
-cell failure is the principal factor re-
sponsible for the development of overt
hyperglycemia (13). Prediction models
for type 2 diabetes that have been devel-
opedbasedonmeasurementofthefasting
state include FPG and lipid concentra-
tions, waist circumference, and blood
pressure. All of these risk factors are com-
ponents of the metabolic (insulin resis-
tance) syndrome, which itself is a
predictoroffuturetype2diabetesinnon-
diabetic individuals (14). Thus, these risk
factors would be expected to correlate
strongly with the presence of insulin re-
sistance but less well with impairment in
-cell function. In a recent publication,
wedemonstratedthatthe1-hplasmaglu-
cose concentration correlates strongly
with indexes of both insulin resistance
and insulin secretion and is a better pre-
dictor for future type 2 diabetes than ei-
ther the FPG concentration or the 2-h
plasma glucose concentration in Mexi-
can-American individuals (15). Further,
we demonstrated that addition of the 1-h
plasmaglucoseconcentrationtoapredic-
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signiﬁcantly improved the ability of the
model to predict future type 2 diabetes in
Mexican Americans (15) and was able to
stratify subjects with NGT and IGT into
low-, intermediate-, and high-risk groups
(10).
Because the relative contributions of
insulin resistance and impaired -cell
function may vary among various ethnic
groups (16), the aim of this study was to
assesstheabilityofthe1-hplasmaglucose
concentration during an OGTT to predict
future risk of type 2 diabetes compared
with the fasting and 2-h plasma glucose
concentrations in a European Caucasian
population. We also examined whether
addition of the 1-h plasma glucose con-
centration to models based on fasting
measurements would enhance their pre-
dictive value for development of future
type 2 diabetes.
RESEARCH DESIGN AND
METHODS— The participants in this
study were subjects who participated in
the Botnia Study (17), were free of diabe-
tes at baseline, had their plasma glucose
and insulin concentrations measured
during an OGTT, and had a repeat OGTT
after 7–8 years. Subjects were classiﬁed
into various categories of glucose toler-
ance based on their fasting and 2-h
plasma glucose concentrations during an
OGTT, according to the American Diabe-
tes Association (ADA) criteria (18).
All subjects received a standard 75-g
OGTT after a 12-h overnight fast. Plasma
glucoseandseruminsulinconcentrations
were measured at 0, 30, 60, and 120 min.
Anthropometric and lipid proﬁles were
also obtained at baseline. Subjects were
followed for 7–8 years, and glucose toler-
ance status was determined at follow-up
witharepeatOGTTaccordingtotheADA
criteria (18). A detailed description of the
study design was previously published
elsewhere (17).
Analytical methods
Plasma glucose was measured with the
glucose oxidation method using a Beck-
man glucose analyzer (Beckman Instru-
ments, Fullerton, CA). Serum insulin was
measured in duplicate by radioimmuno-
assay (Pharmacia, Uppsala, Sweden).
Calculations
The diagnosis of diabetes was based on
ADA criteria (18). The metabolic syn-
drome was diagnosed according to Adult
Treatment Panel III criteria (19).
Areas under the glucose and insulin
curves were calculated by the trapezoid
rule. The Matsuda index of insulin sensi-
tivity was calculated as reported previ-
ously (20). The insulinogenic index was
calculated by dividing the increment in
serum insulin by the increment in plasma
glucose from 0 to 30 min of the OGTT
(I0–30/G0–30). The insulin secretion/
insulin resistance (disposition) index was
calculated as the product of the insulino-
genic index across 120 min (I0–120/
G0–120) and the Matsuda index of insulin
sensitivity. We tested the following pre-
diction models that rely on fasting mea-
surements: 1) a previously described,
multivariatemodel(SanAntonioDiabetes
Prediction Model [SADPM]) for predict-
ing future type 2 diabetes (3), which in-
cludes age, sex, ethnicity, BMI, blood
pressure, and FPG, triglyceride, and HDL
concentrations; 2) the ATP III criteria for
the metabolic syndrome (19); 3) a risk
score index (Score Model I) based on age,
obesity measurements, use of hyperten-
sivemedications,andfamilyhistoryofdi-
abetes (6); and 4) a diabetes risk score
based on sex, age, and measurement of
FPG and triglyceride concentrations (8).
The predictive value of these four mod-
els also was evaluated after addition of
the 1-h plasma glucose concentration
during the OGTT. We also evaluated
the risk of future diabetes using a tree
model analysis.
Tree model analysis
Recursively partitioned classiﬁcation
trees (21) were used to model the rela-
tionship between the future risk of type 2
diabetes and 1) the 1-h plasma glucose
concentration during the OGTT and 2)
the presence or absence of the metabolic
syndrome. Subjects were classiﬁed into
groups with NGT, IGT, impaired fasting
glucose(IFG),orcombinedglucoseintol-
erance (CGI) (IGT  IFG) according to
ADA criteria (18). Sequential partitioning
of individuals within each glucose toler-
ance group (NGT, IGT, IFG, and CGI)
based on a 1-h plasma glucose concentra-
tion  or 155 mg/dl and the presence
or absence of the metabolic syndrome
producedsubgroupsofindividualswitha
homogeneous risk for future type 2 dia-
betes. Subgroups with a risk for future
type 2 diabetes that was 2.5% over 7–8
years were considered to have a low risk
for future type 2 diabetes. A risk between
5and10%over7–8yearswasconsidered
to represent intermediate risk. A risk
15% over 7–8 years was considered to
represent high risk.
Statistical methods
Variables are presented as means  SD.
The signiﬁcance of the mean differences
wastestedwithANOVA.Statisticalsignif-
icance was considered at the level of P 
0.05. Assessment of the predictive dis-
crimination of the various models was
madeusingthereceiveroperatingcharac-
teristic (ROC) curve by plotting the sen-
sitivity against the corresponding false-
positive rate. The area under the ROC
(aROC) curve was used as a measure of
how well a continuous variable predicts
the development of type 2 diabetes. To
examine whether differences between
two aROC curves were statistically differ-
ent, the algorithm developed by DeLong
et al. (22) was used. Statistical analyses
were performed with the SPSS statistical
software system.
RESULTS— Table 1 presents the an-
thropometric, laboratory, and clinical
characteristicsofthestudypopulation.Of
the 2,442 study participants, 1,110 had
NGT,949hadIFG,123hadIGT,and260
had CGI at baseline. A total of 124 sub-
jects (5.1%) developed type 2 diabetes
over the 7–8 years of follow-up. The con-
version rates to type 2 diabetes were 2.4,
5.1, 11.5, and 13.5% for subjects with
NGT, IFG, IGT, and CGI, respectively.
The aROC curve was used to evaluate
the predictive power of the various pre-
diction models. All plasma glucose con-
centrations (0, 30, 60, and 120 min)
duringtheOGTTweresigniﬁcantpredic-
tors for future risk of type 2 diabetes (Ta-
ble 2). However, the plasma glucose
concentration at 60 min was the stron-
gest predictor of future risk for type 2
diabetes. The aROC curve for the FPG
concentration in this population was
signiﬁcantly less than the aROC curve
for the 30- and 60-min plasma glucose
concentrations during the OGTT. The
aROC curve for the 120-min plasma
glucose concentration was smaller
(0.688) than the aROC curve for both
the30-and60-minplasmaglucosecon-
centrations during the OGTT (Table 2).
The aROC curve for A1C (0.697) was
similartothatforFPG(0.672).Theincre-
mental area under the glucose curve dur-
ing the OGTT (G0–120) was a strong
predictor for the future risk of type 2 di-
abetes and had an aROC curve (0.770)
comparable with that for the 1-h plasma
glucose concentration (0.795).
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centration is the strongest predictor for
future risk of type 2 diabetes, we tested
whether addition of the 1-h plasma glu-
cose concentration to prediction models
(SADPM, ATP III criteria, Score Model I,
and Score Model II) based on measure-
ments made during the fasting state im-
proves their predictive power. All four
models performed well in predicting the
future risk for type 2 diabetes, and the
aROC curve ranged from 0.64 to 0.74.
However, addition of the 1-h plasma glu-
cose concentration markedly enhanced
the predictive power for each of the four
models, resulting in an aROC curve 0.8
(Table 2).
We demonstrated previously that a
1-hplasmaglucosecutpointof155mg/dl
during the OGTT and the presence of the
metabolicsyndromecouldclassifynondi-
abeticsubjectsintothreeriskgroups:low,
intermediate, and high (10). In the
present study, we constructed a tree
model on the basis of glucose intolerance
status, the 1-h plasma glucose concentra-
tion, and the presence of the metabolic
syndrome to classify the risk for future
type 2 diabetes. The ROC curve for this
model was 0.92. In this model, individu-
als were divided, according to the ADA
criteria,intofourgroups(NGT,IFG,IGT,
and CGI) based on their fasting and 2-h
plasma glucose concentrations. Individu-
als in each group were further divided
into two subgroups based on their 1-h
plasma glucose concentration ( or
155 mg/dl). Figure 1 depicts the inci-
dence of type 2 diabetes based on the 1-h
plasma glucose concentration and the
presence or absence of the metabolic syn-
drome in each glucose tolerance group.
Although, as a whole, subjects with NGT
had a low risk for developing type 2 dia-
betes (2.4%), subjects with NGT with a
Table 1—Anthropometric, clinical, and laboratory characteristics of the study population
NGT IFG IGT CGI
Total
population ANOVA
n 1,110 949 123 260 2,442
Sex (female/male) 661/449 427/522 72/51 155/105 1,315/1,127 0.0001
Age (years) 45  14 6  15 0  25 2  14 6  0.3 0.0001
BMI (kg/m
2) 24.1  0.7 23.5  0.3 24.9  0.2 25.6  0.2 25.8  0.08 0.0001
Waist (cm) 84.5  0.4 88.4  0.4 90.1  1.1 92.7  0.8 87.2  0.24 0.0001
FPG (mg/dl) 92  1 108  19 3  1 110  1 100  0.2 0.0001
2-h plasma glucose (mg/dl) 99  1 109  1 158  2 158  1 112  0.6 0.0001
Total cholesterol (mmol/l) 5.4  0.03 5.6  0.04 5.6  0.09 5.8  0.07 5.6  0.02 0.01
HDL cholesterol (mmol/l) 1.42  0.01 1.37  0.03 1.33  0.03 1.29  0.02 1.38  0.01 0.05
Triglycerides (mmol/l) 1.15  0.02 1.31  0.03 1.51  0.08 1.65  0.06 1.28  0.02 0.05
Blood pressure (mmHg) 125/77 129/78 132/81 139/83 128/78 0.001
Metabolic syndrome (%) 8.1 30.5 22.8 55.4 22.6 0.0001
No. converted to diabetes 27 48 14 35 124 0.0001
% converted to diabetes 2.4 5.1 11.5 13.5 5.1 0.0001
Data are means  SD unless indicated otherwise.
Table 2—aROC curve and simple correlation (Pearson) between plasma glucose concentration during the OGTT and log transformation of
insulin secretion and insulin sensitivity indices
aROC curve
Matsuda
index I0–30/G0–30 I0–120/G0–120
I0–30/G0–30 
Matsuda
I0–120/G0–120 
Matsuda
FPG 0.672* 0.38§ 0.06 0.02 0.33§ 0.24§
PG at 30 min 0.735* 0.45§ 0.42§ 0.39§ 0.73§ 0.62§
PG at 60 min 0.795 0.50§ 0.40§ 0.55§ 0.73§ 0.72§
PG at 120 min 0.688* 0.46§ 0.11§ 0.34§ 0.42§ 0.58§
A1C 0.679* 0.18§ 0.06§ 0.1 0.19§ 0.19§
G0–120 0.77† 0.48§ 0.42§ 0.6§ 0.73§ 0.83§
Score Model I 0.646* 0.36§ 0.02 0.015 0.05 0.07
Score Model II 0.74* 0.40§ 0.04 0.07 0.01 0.07
SADPM 0.743* 0.51§ 0.025 0.042 0.333§ 0.351§
MS 0.72* 0.56§ 0.017 0.015 0.032 0.316§
MS  G60 0.813‡ 0.53§ 0.23§ 0.272§ 0.53§ 0.53§
Model I  G60 0.805‡ 0.38§ 0.13§ 0.09 0.11§ 0.22§
Model II  G60 0.822‡ 0.43§ 0.11§ 0.09 0.11§ 0.22§
SADPM  G60 0.832‡ 0.52§ 0.214§ 0.256§ 0.52§ 0.51§
*P0.001comparedwiththeaROCcurveforplasmaglucoseconcentrationat60min.†P0.05versustheaROCcurveforplasmaglucoseconcentration60min.
‡P  0.0001 compared with the aROC curve of the same model without G60. §P  0.0001. P  0.05. G60, plasma glucose concentration at 60 min during the
OGTT; PG, plasma glucose; MS, metabolic syndrome; SADPM, San Antonio Diabetes Prediction Model.
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mg/dl had a signiﬁcantly increased risk
(8.5%) for future type 2 diabetes compared
with subjects with NGT with a 1-h plasma
glucose concentration 155 mg/dl (1.3%)
(P0.0001).Furtherdivisionofthisgroup
based on the presence or absence of the
metabolic syndrome demonstrated that
subjects with NGT with a 1-h plasma glu-
cose concentration 155 mg/dl and the
metabolicsyndromehada14.3%incidence
rate of type 2 diabetes compared with a
7.4%incidencerateforsubjectswithoutthe
metabolic syndrome.
Subjects with both IFG and IGT with
a1-hplasmaglucoseconcentration155
mg/dl and the metabolic syndrome had a
high risk for future type 2 diabetes (15.1
and 23%, respectively), whereas subjects
with IFG and IGT with a 1-h plasma glu-
cose concentration 155 mg/dl without
the metabolic syndrome had a very low
risk for future type 2 diabetes (0.8 and
0%, respectively). Subjects with a 1-h
plasma glucose concentration 155
mg/dl with the metabolic syndrome or a
1-h plasma glucose concentration 155
mg/dl without the metabolic syndrome
had an intermediate risk for future type 2
diabetes (5–10%).
Subjects with CGI and the metabolic
syndrome had a very high risk for future
type 2 diabetes (20%), whereas none of
the subjects with a 1-h plasma glucose
concentration 155 mg/dl without the
metabolic syndrome developed type 2 dia-
betes. Subjects with a 1-h plasma glucose
concentration 155 mg/dl without the
metabolic syndrome had an intermediate
(7.2%) risk for future type 2 diabetes.
CONCLUSIONS— Clinical trials
have demonstrated that lifestyle interven-
tion and pharmacological therapy can re-
duce the incidence rate of type 2 diabetes
among high-risk individuals (2), and an
ADA consensus statement has recom-
mendedtreatmentwithmetformin,inad-
dition to diet and exercise, in high-risk
individuals with IGT or IFG (23). This
recommendation for pharmacologic in-
tervention in “pre-diabetic” individuals
underscores the need for models that re-
liably identify subjects at increased risk
forfuturedevelopmentoftype2diabetes.
The results of this study demonstrate that
in a Scandinavian Caucasian population,
the predictive value for future type 2 dia-
betes using the 1-h plasma glucose con-
centration is superior to that for the 2-h
plasmaglucoseconcentrationandmodels
based only on measurements taken dur-
ing the fasting state. In this Scandinavian
Caucasian population, as previously
demonstrated in a Mexican-American
population, the plasma glucose concen-
tration at 1 h during the OGTT is a useful
tool that can be used to stratify the risk of
future type 2 diabetes.
Subjects with IGT (2-h plasma glu-
cose concentration 	 140–199 mg/dl)
have an increased risk for future type 2
diabetes, and intervention studies sys-
tematically have recruited subjects with
IGT to test the efﬁcacy of interventions
aimed to reduce the conversion rate of
IGT to type 2 diabetes. Because perfor-
mance of an OGTT in routine clinical
practiceiscomplicatedandtimeconsum-
ing, investigators have developed predic-
tion models based on measurements
made during the fasting state to predict
the risk of future type 2 diabetes (3–8).
These models perform equally well in pre-
dicting future type 2 diabetes compared
with the 2-h plasma glucose concentration
during the OGTT. Furthermore, addition
of the 2-h plasma glucose value to these
models did not improve their predictive
power (3). In this study we demonstrated
thatthe1-hplasmaglucoseconcentration
issuperiortoboththe2-hplasmaglucose
concentration and predictive models
based only on fasting measurements in
predicting the future risk for type 2 dia-
betes. Furthermore, addition of the 1-h
plasma glucose concentration to models
based only on fasting measurements
markedly improved their predictive
power (Table 2).
A1C, which reﬂects the mean plasma
glucose concentration over the prior 3
months, has predictive power similar to
that of the FPG value, and it was much
weaker than the 1-h plasma glucose con-
centrationinpredictingthefutureriskfor
type 2 diabetes. Of note, the optimal A1C
cut point for predicting future type 2 di-
Figure1—Treemodelbasedontheglucosetolerancestatus([A]NGT,[B]IFG,[C]IGT,or[D]CGI[IFGIGT])ofthesubjects,1-hplasmaglucose
concentrationor155mg/dl,andthepresenceorabsenceofthemetabolicsyndrome.Thenumbersineachnodulerepresentthenumberofsubjects
converting to diabetes/total number of subjects in each particular group and the incidence rate of conversion to diabetes over 8 years. 1 h PG, 1-h
plasma glucose concentration during the OGTT; MS, metabolic syndrome present; MS
, metabolic syndrome absent.
Fasting and postload glucose and diabetes risk
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range considered normal.
The parameters used in the fasting
models (BMI, waist circumference, lipid
proﬁle, fasting glucose, and blood pres-
sure) are components of the metabolic or
insulinresistancesyndrome,and,assuch,
they have greater sensitivity in assessing
insulin resistance than -cell function.
Similarly, A1C correlated poorly with in-
dexes of -cell function (Table 2). Con-
versely, measurement of the postload
plasma glucose concentrations (e.g.,
1-h plasma glucose concentration and
G0–120) correlated well with indexes of
-cell function (Table 2). Thus, it should
be emphasized that progressive -cell
failure is the principal factor responsible
for the progressive decline in glycemic
control as individuals progress from NGT
to IGT to type 2 diabetes (11,16,24,25).
In this study, we have shown that in a
Caucasian population, the 1-h plasma
glucose concentration correlates better
with OGTT-derived indexes of -cell
functionthanthe2-hplasmaglucosecon-
centration or prediction models based on
fasting measurements; these results are
similar to our previous results in Mexican
Americans. The strong correlation be-
tween the 1-h plasma glucose concentra-
tionand-cellfunctioncouldexplainthe
superior performance of the 1-h plasma
glucose concentration in predicting the
risk of future type 2 diabetes compared
with 2-h plasma glucose concentration
and especially compared with models
based only on fasting measurements. Simi-
larly, G0–120, which is highly dependent
on -cell function, also is a strong predic-
tor for future risk of type 2 diabetes. These
results indicate that assessment of future
risk for type 2 diabetes requires that the
-cell be “stressed” to accurately assess its
function. In contrast, prediction models
based on measurements made during fast-
ing states do not have the ability to assess
-cell function and, therefore, have modest
predictive power for future diabetes risk
comparedwiththe1-hplasmaglucosecon-
centration after a glucose challenge.
In this study, we also demonstrated
thatthe1-hplasmaglucoseconcentration
is a useful measure to stratify Caucasian
subjects into low, intermediate, and high
risk categories. In general, subjects with
NGThavelowriskforprogressiontotype
2 diabetes (1% annual rate) (2). How-
ever, 30–40% of individuals who de-
velop type 2 diabetes have NGT at
baseline (2) and, in the present study,
22% of subjects who developed type 2
diabetes had NGT at baseline. In this
study we demonstrate that subjects with
NGT with a 1-h plasma glucose concen-
tration155mg/dlhaveagreaterriskfor
future type 2 diabetes (8.5%) than sub-
jects with NGT with a 1-h plasma glucose
concentration 155 mg/dl (1.3%) (P 
0.00001). Further, subjects with NGT
with a 1-h plasma glucose concentration
155 mg/dl, who also fulﬁll the ATP III
criteriaforthemetabolicsyndrome,hada
15% risk for future type 2 diabetes. Thus,
thegroupofsubjectswithNGTwitha1-h
plasma glucose concentration 155
mg/dlandthemetabolicsyndromehavea
high risk for the development of type 2
diabetes, and their risk exceeds that of
subjectswithIFGorIGT.Consistentwith
an ADA consensus statement (23), this
group of high-risk individuals with NGT
could beneﬁt from an intervention pro-
gramincludingdietandexerciseandpos-
sibly pharmacotherapy to reduce their
future risk for diabetes.
Subjects with CGI have the greatest
risk (13.5%) for future type 2 diabetes,
whereassubjectswithisolatedIFGorIGT
have an intermediate risk between those
with CGI and NGT. However, within the
IFG and IGT groups, the 1-h plasma glu-
cose concentration during the OGTT also
identiﬁes high-risk individuals. Thus,
subjects with IFG and IGT with a 1-h
plasma glucose concentration 155
mg/dl have a 2% risk compared with a
10% risk for those with a 1-h plasma
glucose concentration 155 mg/dl.
Thus,theplasmaglucoseconcentrationat
1hduringtheOGTT,independentofglu-
cose tolerance status, is a strong predictor
for future type 2 diabetes. Subjects with
NGT,IFG,andIGTwhofulﬁlltheATPIII
criteria for metabolic syndrome and have
a1-hplasmaglucoseconcentration155
mg/dl have the greatest risk (15%) for
future type 2 diabetes, and, in addition to
lifestyle intervention, pharmacological
therapy should be considered in these
subjects. Conversely, subjects with a 1-h
plasma glucose concentration 155
mg/dl without the metabolic syndrome
have a very low risk for future diabetes
(1%) and, therefore, no intervention is
necessary in this group.
In summary, measurement of the
postload plasma glucose concentration
has additive value to models based only
onfastingmeasurementsinpredictingthe
future risk for type 2 diabetes. Similar to
results in Mexican Americans, the plasma
glucose concentration at 1 h during the
OGTT is a strong predictor of future risk
for type 2 diabetes in Caucasians, and a
1-hplasmaglucosecutpointof155mg/dl
plus the ATP III criteria for the metabolic
syndrome can be used to stratify nondia-
betic subjects into low-, intermediate-,
and high-risk categories.
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